Literature DB >> 3155533

Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction.

M M Zatz, A L Goldstein.   

Abstract

The effect of thymosin on the murine thymocyte mixed lymphocyte response was studied. Thymosin fraction 5 (TF5) caused a two- to threefold enhancement of the proliferative response and production of IL 2 when murine thymocytes were cultured with alloantigenic stimulator cells. Production of a second lymphokine, CSF, was increased up to sevenfold. The target cell for thymosin was a mature T cell, because the PNA- subpopulation of thymocytes, as well as peripheral lymph node lymphocytes, responded to culture with TF5 and alloantigen by enhanced proliferation and lymphokine production. The active component of TF5 appears to be one or more as yet unidentified peptides, because neither of the well-characterized TF5 component peptides, alpha 1 or beta 4, were active. After incubation with TF5 in primary culture, cells remaining after 10 to 14 days were increased both in number and in secondary response to alloantigen, as measured by lymphokine production. These results suggest that TF5 contains one or more biologically active components which can modulate mature T cell activity and lymphokine production, and which provide the basis for understanding some of the previously reported diverse effects of thymosin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy.

Authors:  D Chadwick; J Pido-Lopez; A Pires; N Imami; F Gotch; J S Villacian; S Ravindran; N I Paton
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  Therapy of secondary T-cell immunodeficiencies with biological substances and drugs.

Authors:  J W Hadden; E M Hadden
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

Authors:  M B Sztein; S A Serrate; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Analysis of thymic stromal cell subpopulations grown in vitro on extracellular matrix in defined medium. III. Growth conditions of human thymic epithelial cells and immunomodulatory activities in their culture supernatant.

Authors:  L Schreiber; I Eshel; A Meilin; Y Sharabi; J Shoham
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

5.  Modulation of NK activity by thymic hormones: in vitro effects of thymostimulin.

Authors:  A M Liberati; S Cinieri; M Fizzotti; M Schippa; S Ascani; V De Angelis; M Senatore; L Palmisano
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Thymus lymphocytes in uraemic rats and the effect of thymosin fraction 5 in vivo.

Authors:  S Ikemoto; M Kamizuru; N Hayahara; S Okamoto; S Wada; T Kishimoto; M Maekawa
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

7.  Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

Authors:  J Zielasek; V Burkart; P Naylor; A Goldstein; U Kiesel; H Kolb
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

8.  Molecular characterization, tissue distribution, subcellular localization and actin-sequestering function of a thymosin protein from silkworm.

Authors:  Wenping Zhang; Changrong Zhang; Zhengbing Lv; Dailing Fang; Dan Wang; Zuoming Nie; Wei Yu; Hanglian Lan; Caiying Jiang; Yaozhou Zhang
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.